Form 4 for DXCM Dexcom
Accepted 2022-02-14 00:00:00 ET · period of report 2022-02-10 · accession 0001093557-22-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2022-02-14 | 2022-02-10 | DXCM | KAHN BARBARA | Dir | S - Sale | $442.35 | -4,666 | 3,000 | -61% | -$2.06M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-10 | S | D | 100 | $428.55 | 7,566 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 2 | Common | Common Stock | 2022-02-10 | S | D | 100 | $430.06 | 7,466 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 3 | Common | Common Stock | 2022-02-10 | S | D | 100 | $435.64 | 7,366 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 4 | Common | Common Stock | 2022-02-10 | S | D | 100 | $438.21 | 7,266 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 5 | Common | Common Stock | 2022-02-10 | S | D | 200 | $440.85 | 7,066 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F3) This transaction was executed in multiple trades at prices ranging from $440.65 to $441.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 6 | Common | Common Stock | 2022-02-10 | S | D | 476 | $442.18 | 6,590 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F4) his transaction was executed in multiple trades at prices ranging from $441.69 to $442.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 7 | Common | Common Stock | 2022-02-10 | S | D | 1,147 | $434.36 | 5,443 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F5) This transaction was executed in multiple trades at prices ranging from $434.28 to $434.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 8 | Common | Common Stock | 2022-02-10 | S | D | 443 | $443.56 | 5,000 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F6) This transaction was executed in multiple trades at prices ranging from $442.93 to $443.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 9 | Common | Common Stock | 2022-02-10 | S | D | 400 | $444.80 | 4,600 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F7) This transaction was executed in multiple trades at prices ranging from $444.35 to $445.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 10 | Common | Common Stock | 2022-02-10 | S | D | 200 | $445.85 | 4,400 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F8) his transaction was executed in multiple trades at prices ranging from $445.54 to $446.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 11 | Common | Common Stock | 2022-02-10 | S | D | 200 | $447.35 | 4,200 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F9) This transaction was executed in multiple trades at prices ranging from $447.06 to $447.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 12 | Common | Common Stock | 2022-02-10 | S | D | 400 | $448.98 | 3,800 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F10) This transaction was executed in multiple trades at prices ranging from $448.53 to $449.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 13 | Common | Common Stock | 2022-02-10 | S | D | 200 | $450.07 | 3,600 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F11) This transaction was executed in multiple trades at prices ranging from $449.61 to $450.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 14 | Common | Common Stock | 2022-02-10 | S | D | 200 | $451.29 | 3,400 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F12) This transaction was executed in multiple trades at prices ranging from $450.96 to $451.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |
| 15 | Common | Common Stock | 2022-02-10 | S | D | 400 | $452.50 | 3,000 | I by Trust | — | — | (F1) On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. (F13) This transaction was executed in multiple trades at prices ranging from $451.96 to $452.94. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. (F2) Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |